Physician profile
Kerri E Carr
NPI 1508434283
$3,435.99
in general payments reported to CMS, 2019-2025
33 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,276 · 2022: $1,455 · 2023: $385 · 2024: $166 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $705.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $612.80 | 2021-2022 | |
| Abbvie INC. | $386.44 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $367.14 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $356.92 | 2022-2023 | Ponvory |
| Acorda Therapeutics, INC | $180.90 | 2021-2022 | |
| Novocure INC. | $164.53 | 2023-2025 | Optune |
| Horizon Therapeutics Plc | $135.01 | 2022 | |
| Genentech USA, INC. | $107.42 | 2021 | |
| Medical Device Business Services, INC. | $95.48 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $93.71 | 2021 | |
| Sk Life Science, INC. | $91.55 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $88.82 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $87.30 | 2022 | |
| Ucb, INC. | $65.63 | 2021-2022 | |
| Greenwich Biosciences, INC. | $65.00 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $58.56 | 2021-2022 | |
| Boston Scientific Corporation | $52.99 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Csl Behring | $46.51 | 2022 | |
| Depuy Synthes Sales INC. | $43.96 | 2024 | Spine & Trauma 3d Navigation |
| Eisai INC. | $42.32 | 2021-2022 | |
| Biogen, INC. | $40.53 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $32.83 | 2021-2022 | |
| Solventum Corporation | $31.37 | 2025 | V.A.C. Veraflo, Prevena |
| Karl Storz Endoscopy-America | $28.88 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $27.74 | 2021 | |
| Stryker Corporation | $23.85 | 2023 | Universal Neuro 3 |
| Lemaitre Vascular, INC. | $22.77 | 2025 | Anastoclip Gc 8cm (Medium) |
| Orthofix Medical, INC. | $19.43 | 2025 | Cervical-Stim |
| Supernus Pharmaceuticals, INC. | $14.30 | 2021 | |
| Purdue Pharma L.P. | $13.59 | 2025 | Nalmefene Hydrochloride |
| Mdd US Operations, LLC | $13.21 | 2022 | |
| Lundbeck LLC | $12.67 | 2022 | |
| Sobi, INC | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerri Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.